weight loss drugs – Page 2 – Diet Business Watch

Novo Nordisk Obesity Drugs Sales Slow – Compounders Still Selling illegally

August 6, 2025 Sales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of U.S. tariffs, coupled with continued competition from compounded drugs sold illegally. Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and […]

Novo Nordisk Obesity Drugs Sales Slow – Compounders Still Selling illegally Read More »

Noom To Offer GLP-1 Microdose Plan

News / John LaRosa

August 5, 2025 Noom is not giving up in the fight to provide GLP-1 drugs, despite pressure from Novo and Eli Lilly to stop selling compounded meds. It is now offering a “micro dose” plan. This program provides access to GLP-1 medication (if prescribed by a clinician), but at a lower, “microdose” level compared to

Noom To Offer GLP-1 Microdose Plan Read More »

Weight Watchers Expands Collaboration With Novo Nordisk

News / John LaRosa

July 2, 2025 Weight Watchers announced an expanded collaboration with Novo Nordisk, which includes increased access to authentic, FDA-approved Wegovy® (semaglutide) injection through Weight Watchers Clinic. As part of the collaboration, Weight Watchers Clinic members will benefit from a simplified prescription process via NovoCare® Pharmacy. CenterWell Pharmacy®, which serves as the dispensing pharmacy for the

Weight Watchers Expands Collaboration With Novo Nordisk Read More »

Novo Nordisk Ends Wegovy Sales Deal With Hims & Hers

News / John LaRosa

June 24, 2025 Hims & Hers stock plummeted nearly 35% Monday after Novo Nordisk announced it was ending a collaboration to make its blockbuster weight-loss drug, Wegovy, available on Hims’ telehealth platform. Novo Nordisk said that Hims & Hers was breaking the law by continuing to sell copycat semaglutide, the key ingredient in Wegovy, alongside

Novo Nordisk Ends Wegovy Sales Deal With Hims & Hers Read More »

Weight Watchers Reorganization Plan Confirmed

News / John LaRosa

June 18, 2025 Following approval of its Plan of Reorganization, WW is on track to exit the court-supervised financial reorganization process as early as next week. “This is a meaningful turning point for WeightWatchers,” said Tara Comonte, CEO of Weight Watchers. “We’ve taken decisive action to significantly strengthen our financial foundation and will emerge with

Weight Watchers Reorganization Plan Confirmed Read More »

National Consumers League Launches “The Weight Truth,” to Combat GLP-1 Drugs Disinformation

News / John LaRosa

May 1, 2025 The National Consumers League (NCL) – a leading non-profit fighting fraud in the marketplace – today released a white paper as a blueprint for policy changes to combat the flood of false information circulating online about GLP-1 products and launched an ambitious national anti-disinformation effort called the Weight Truth with the online

National Consumers League Launches “The Weight Truth,” to Combat GLP-1 Drugs Disinformation Read More »

Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over

News / John LaRosa

Feb. 25, 2025 Eli Lilly said today that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. Zepbound was originally sold in injectable pens at

Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over Read More »

Medifast Reports Q4 and Full Year 2024 Results

News / John LaRosa

Feb. 18, 2025 “This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of a health and wellness market that has been revolutionized by the rising acceptance of GLP-1 medications,” said Dan Chard, Chairman & CEO. Fourth quarter 2024 revenue decreased 37.7% to $119.0

Medifast Reports Q4 and Full Year 2024 Results Read More »

Conflicts in Trump Administration For Support of GLP-1 Meds

Uncategorized / John LaRosa

Feb. 3, 2025 Support for the wildly popular weight loss meds in the new administration appears to be a question mark. Dr. Oz has publicly praised GLP-1s for their benefits, even pitching them on TV and social media channels, according to a Dec. 30 report from The Hill. On the other hand, Mr. Kennedy expressed

Conflicts in Trump Administration For Support of GLP-1 Meds Read More »

The Party Is Almost Over for GLP-1 Compounders

Uncategorized / John LaRosa

January 27, 2025 Shortages is that they don’t last forever, and that applies to compounded weight loss meds. After some legal wrangling, the FDA pulled tirzepatide from its shortage list in December, giving compounders a short grace period to wrap things up. That means people taking the copycats will soon need to switch to the

The Party Is Almost Over for GLP-1 Compounders Read More »